Avecho

Avecho is a company focused on the development and commercialization of novel drug delivery technologies. The company's primary platform technology is called the Advanced Drug Delivery System (ADDS). ADDS is designed to improve the oral bioavailability of poorly soluble drugs. It works by encapsulating active pharmaceutical ingredients within a lipid-based formulation that is then absorbed more efficiently by the body. This technology aims to increase the amount of drug that reaches the bloodstream, potentially leading to lower required doses and reduced side effects.

The company has a pipeline of drug candidates utilizing the ADDS technology across various therapeutic areas. These include treatments for fatty liver disease, including non-alcoholic steatohepatitis (NASH), and other metabolic disorders. Avecho collaborates with pharmaceutical partners to advance its drug candidates through clinical trials and towards potential market approval. Their business model involves both in-house development and out-licensing of their ADDS technology. Avecho is committed to addressing unmet medical needs through its innovative drug delivery solutions.